加拿大PreMD Inc www.premdinc.com
依一份美國(guó)心臟學(xué)期刊新近發(fā)表的資料，有一個(gè)特殊的非侵入性皮膚固醇測(cè)試，可以使用于偵測(cè)早期血管性疾病。利用PREVU(*) Point of Care (POC) Skin Sterol Test這項(xiàng)非侵入性產(chǎn)品便可以用來測(cè)試皮膚組織膽固醇。這種皮膚組織膽固醇和心肌梗塞及中風(fēng)的標(biāo)準(zhǔn)風(fēng)險(xiǎn)指標(biāo)，也就是頸動(dòng)脈內(nèi)膜中層厚度(carotid intima media thickness, CIMT)有關(guān)聯(lián)性。PreMD Inc公司的執(zhí)行長(zhǎng)及總裁Dr. Brent Norton說，公司正在進(jìn)行中的 600人臨床研究 (PASA) 將會(huì)在這個(gè)令人興奮的成果方面，繼續(xù)擴(kuò)大研究皮膚組織膽固醇和CIMT的關(guān)聯(lián)性。
PreMD Inc. is dedicated to saving and improving people’s lives with simple, painless and patient-friendly tests that can detect life-threatening illnesses at an early stage. Our tests do not require any patient preparation or dietary restrictions and can be performed at the point of care, in a laboratory setting and, in some cases, even at home. 
Cardiovascular Assessment 

Our cardiovascular risk assessment technology, PREVU* Skin Sterol Test, assesses a patient’s risk of heart disease by non-invasively measuring the amount of cholesterol in the skin tissues. 
Cancer Screening Tests

PreMD’s non- or minimally-invasive tests for early-stage colorectal, lung and breast cancers detect a cancer-associated sugar in a sample of rectal mucus, sputum and breast nipple aspirate fluid, respectively. Our cancer tests are in development. 
Our Model for Success

PreMD in-licenses proven technologies that target medical conditions where there is a well-defined, urgent need for tests to assess risk or screen for disease. 
We then develop and realize the potential of each technology. This includes managing clinical trials, which are largely funded by third parties, obtaining patent protection, and navigating the regulatory process. At the appropriate time, we aim to out-license our technologies to a strategic partner for commercialization.
This cost-effective, low-risk business model creates a substantial platform for profitability as PreMD’s products are commercialized.